Noxafil Dosage/Direction for Use

Treatment should be initiated by a physician experienced in the management of fungal infections or in the supportive care of high-risk patients for which posaconazole is indicated as prophylaxis.
Recommended dose is shown in Table 5. (See Table 5.)

Click on icon to see table/diagram/image

Special populations: Renal impairment: An effect of renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: Limited data on the effect of hepatic impairment (including Child-Pugh C classification of chronic liver disease) on the pharmacokinetics of posaconazole demonstrate an increase in plasma exposure compared to subjects with normal hepatic function, but do not suggest that dose adjustment is necessary (see Precautions and Pharmacology: Pharmacokinetics under Actions). It is recommended to exercise caution due to the potential for higher plasma exposure.
Paediatric population: The safety and efficacy of posaconazole oral suspension have not been established in children and adolescents aged below 18 years. Currently available data are described in Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions, but no recommendation on a posology can be made.
Method of administration: For oral use.
The oral suspension must be shaken well before use.